|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000037418 |
|
最近更新日期: Date of Last Refreshed on: |
2020-08-28 04:54:27 |
|
注册时间: Date of Registration: |
2020-08-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于人工智能大数据平台健康管理下中医药防治MCI的临床干预研究 |
|
Public title: |
Research on clinical intervention of TCM Prevention and treatment of MCI based on artificial intelligence big data platform health management |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中医内科学 |
|
Scientific title: |
Internal medicine of traditional Chinese Medicine |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
ChiMCTR2000003810 |
|
申请注册联系人: |
顾超 |
研究负责人: |
顾超 |
|
Applicant: |
Gu Chao |
Study leader: |
Gu Chao |
|
申请注册联系人电话: Applicant telephone: |
13611793374 |
研究负责人电话: Study leader's telephone: |
13611793374 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
shdoctorchao@163.com |
研究负责人电子邮件: Study leader's E-mail: |
shdoctorchao@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
上海中医药大学附属龙华医院 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
上海市宛平南路725号3号楼3楼9病区 |
研究负责人通讯地址: |
上海市宛平南路725号 |
|
Applicant address: |
No. 725 South Wanping Rd,Shanghai |
Study leader's address: |
Shanghai Longhua University Hospital of traditional Chinese Medicine |
|
申请注册联系人邮政编码: Applicant postcode: |
200032 |
研究负责人邮政编码: Study leader's postcode: |
200032 |
|
申请人所在单位: |
上海中医药大学附属龙华医院 |
||
|
Applicant's institution: |
Shanghai Longhua University Hospital of traditional Chinese Medicine |
||
|
研究负责人所在单位: |
上海中医药大学附属龙华医院 |
||
|
Affiliation of the Leader: |
Shanghai Longhua University Hospital of traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2020LHSB059 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海中医药大学附属龙华医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical ethics committee of Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-08-14 00:00:00 |
||
|
伦理委员会联系人: |
陈晓云 |
||
|
Contact Name of the ethic committee: |
Chen Xiao Yun |
||
|
伦理委员会联系地址: |
上海市宛平南路725号 |
||
|
Contact Address of the ethic committee: |
No. 725 South Wanping Rd,Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
13611793374 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
shdoctorchao@163.com |
|
研究实施负责(组长)单位: |
上海中医药大学附属龙华医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市宛平南路725号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 725 South Wanping Rd,Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海申康医院发展中心 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Shenkang Hospital Development Center |
||||||||||||||||||||||
|
Target disease: |
MCI |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
借助大数据信息化,应用人工智能关键技术,建立MCI患者信息化管理系统,并以随机对照的方法,选择特异性反映认知损害特点的指标,观察中医药结合人工智能信息化治疗、管理MCI患者的有效性和安全性,以期为实现早期发现和早期干预MCI,延缓或阻止老年性痴呆的发生发展提供一种治疗选择,充分发挥中医药优势。从而实现信息化结合中医药对该病预防、控制、管理的目的。 |
||||||||||||||||||||||
|
Objectives of Study: |
With the help of big data informatization and the application of key technologies of artificial intelligence, an information management system for patients with MCI is established. With the method of random control, the indicators that specifically reflect the characteristics of cognitive impairment are selected to observe the effectiveness and safety of traditional Chinese medicine combined with artificial intelligence information treatment and management of MCI patients, so as to realize early detection and early intervention of MCI, and delay or prevent senile sex mania The occurrence and development of Dai provide a treatment option, give full play to the advantages of traditional Chinese medicine. So as to achieve the purpose of information technology combined with traditional Chinese medicine in the prevention, control and management of the disease. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①年龄40-85 岁;②主诉记忆减退,并经他人证实记忆困难;③简易精神状态检查(MMSE)评分24-30 分;④汉密尔顿抑郁评定量表得分≤12 分(17 项);⑤无明显的脑血管疾病:Hachinski 缺血评分(HIS)评分≤4 分;⑥筛选前12 个月内CT 或MRI 扫描无感染、梗死或其他局灶性损伤的证据,也无涉及神经疾病的提示性临床症状;可以允许1 个非关键性脑区的腔隙性梗死且不被认为影响了受试者的认知损害;⑦有足够的视觉和听觉分辨力接受神经心理学测试。⑧中医辨证为肾精亏虚、气血亏虚患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
① Age: 40-85 years old; ② chief complaint of memory impairment and memory difficulty confirmed by others; ③ Mini Mental State Examination (MMSE) score of 24-30 points; ④ Hamilton Depression Rating Scale score ≤ 12 points (17 items); ⑤ no obvious cerebrovascular disease: Hachinski ischemic score (his) score ≤ 4; ⑥ CT or MRI within 12 months before screening There was no evidence of infection, infarction or other focal injury, and no suggestive clinical symptoms related to neurological diseases; lacunar infarction in a non critical brain area could be allowed and not be considered to affect the cognitive impairment of the subjects; and (7) sufficient visual and auditory resolution was required for neuropsychological tests. ⑧ TCM Syndrome Differentiation for kidney essence deficiency, Qi and blood deficiency patients. |
||||||||||||||||||||||
|
排除标准: |
①肯定的痴呆:MMSE≤24 分或符合DSM-Ⅳ痴呆诊断标准; ②明显的脑血管疾病:HIS 大于4 分或临床脑梗死;③过去2 年内出现过符合DSM-Ⅳ 标准的中度抑郁或另一种精神疾病;④过去2 年内有酒精或药物滥用或成瘾史(DSM-Ⅳ标准);⑤精神分裂症病史(DSM-Ⅳ标准);⑥任何明显的神经疾病如帕金森病、亨廷顿病、正常颅压脑积水、脑肿瘤、进行性核上麻痹、癫痫、硬膜下水肿、多发性硬化、严重头外伤史伴有持续神经功能缺损或已知的结构性脑异常等;⑦不能配合研究程序。 |
||||||||||||||||||||||
|
Exclusion criteria: |
① Positive dementia: MMSE ≤ 24 points or meeting the DSM - Ⅳ dementia diagnostic criteria; ② obvious cerebrovascular diseases: his greater than 4 points or clinical cerebral infarction; ③ moderate depression or another mental disease in line with DSM - Ⅳ standard in the past two years; ④ the past 2 years He had a history of alcohol or drug abuse or addiction (DSM - Ⅳ standard) within one year; ⑤ history of schizophrenia (DSM - Ⅳ standard); and (6) any obvious neurological diseases such as Parkinson's disease, Huntington's disease, normal intracranial pressure hydrocephalus, brain tumor, progressive supranuclear palsy, epilepsy, subdural edema, multiple sclerosis, severe head trauma, with persistent neurological deficits or known structural brain abnormalities (7) it can not cooperate with the research procedure. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-10-01 00:00:00至 To 2022-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-10-01 00:00:00 至 To 2022-03-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random number table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2023.9 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
2023.9 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |